COMMUNIQUÉS West-GlobeNewswire

-
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
26/09/2025 -
SS Innovations Appoints Naveen Kumar Amar as Chief Financial Officer
26/09/2025 -
Un gala du siècle pour célébrer 100 ans d’espoir, de guérison et d’innovation aux Hôpitaux Shriners pour enfants Canada
26/09/2025 -
Shriners Hospitals for Children Canada Hosts Fundraising Gala Celebrating 100 Years of Hope, Healing, and Innovation
26/09/2025 -
UPDATE -- ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic
26/09/2025 -
New Clue Survey Reveals Misinformation About Reproductive Health is a Top Concern for American Women
26/09/2025 -
Shape Therapeutics Announces Multiple Oral and Poster Presentations at the European Society of Gene & Cell Therapy 32nd Annual Congress
26/09/2025 -
Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
26/09/2025 -
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
26/09/2025 -
Philips unveils latest CT and MR innovations in radiation therapy, advancing precision cancer care at ASTRO 2025
26/09/2025 -
24/7 Market News: Kraig Labs Offers Safer, Natural Alternative to Health Risks from Nylon and Polyester Clothing
26/09/2025 -
BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented
26/09/2025 -
Dogecoin Cash, Inc. (OTCQB: DOGP) Subsidiary PrestoDoctor Expands Telehealth Cannabis Evaluations to Connecticut, Now Operating in 19 States Nationwide
26/09/2025 -
RadNet, Inc. to Present at the Jefferies Healthcare Services Conference on September 29, 2025
26/09/2025 -
ADvantage Therapeutics Awarded $2.5 milion NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic
26/09/2025 -
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation
26/09/2025 -
Harrow to Acquire Melt Pharmaceuticals
26/09/2025 -
Sanuwave Announces Strategic Debt Refinancing with New Credit Facility
26/09/2025 -
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
26/09/2025
Pages